To further study the function of TET2, we established stable HCC cell lines either overexpressing or down-regulating TET2 by transfecting TET2 CRISPR/Cas9 Knockout (KO) or TET2 CRISPR/Cas9 Activation (ACT) plasmids. The gene discussed is TET2; the disease is hepatocellular carcinoma.